Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: MALARONE PEDIATRIC

« Back to Dashboard
Malarone Pediatric is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from five suppliers.

The generic ingredient in MALARONE PEDIATRIC is atovaquone; proguanil hydrochloride. There are fourteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.

Summary for Tradename: MALARONE PEDIATRIC

Suppliers / Packagers: see list16

Pharmacology for Tradename: MALARONE PEDIATRIC

Clinical Trials for: MALARONE PEDIATRIC

Weekly Dosing of Malarone ® for Prevention of Malaria
Status: Completed Condition: Malaria

The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia
Status: Recruiting Condition: Malaria

Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Status: Active, not recruiting Condition: Malaria

Chloroquine Alone or in Combination for Malaria in Children in Malawi
Status: Completed Condition: Plasmodium Falciparum Infection

Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function
Status: Completed Condition: Malaria; Falciparum

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
Status: Not yet recruiting Condition: Rabies

DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria
Status: Not yet recruiting Condition: Falciparum Malaria

Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
Status: Completed Condition: Malaria, Falciparum

Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
Status: Completed Condition: Malaria

Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
Status: Active, not recruiting Condition: Malaria

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
atovaquone; proguanil hydrochloride
TABLET;ORAL021078-002Jul 14, 2000RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn